HBM Healthcare Investments (HBMN) Portfolio Co. Lycia Raises $317.5M, Closes Up 66.7%
HBM Healthcare Investments' portfolio company Lycia Therapeutics raised $317.5M in an IPO, pricing shares at $18 and closing the first day at $30, a 66.7% increase. HBM invested $13.5M and now holds 2.2% of Lycia. Lycia began trading on Nasdaq as LYCA on Oct 23, 2026. According to HBM, this event validates their biotech portfolio exposure.
How this was made
The 30-second read
Why it matters
The IPO provides HBM with liquidity and validates its biotech exposure; Lycia's strong debut may attract further investor interest.
Market read
First‑day price jump and sizable raise make this IPO a notable event for biotech investors and market participants.
What to watch
Potential dilution from future financings and reliance on upcoming trial results for long‑term valuation.
Background
HBM Healthcare Investments announced its portfolio company Lycia Therapeutics' successful IPO.
Ticker impact
Lycia Therapeutics priced an upsized $317.5M IPO at $18 and closed its first day at $30, up 66.7%.
likely upward pressure as traders buy into the IPO momentum
Large capital raise and strong debut price suggest strong demand; early trading may continue to push the stock higher.
Market effects
Biotech IPO activity may lift peer biotech stocks seeking capital.
US Nasdaq sees fresh biotech listing, adding to sector depth.
Large $317.5M raise signals investor appetite for early‑stage biotech globally.
Counterpoint
Post‑IPO sell‑off risk if early investors lock‑up expires or if clinical data disappoints.
Key entities
- InvestorHBM Healthcare Investments
Private investment firm that holds ~2.2% of Lycia after investing $13.5M.
- Biotech CompanyLycia Therapeutics
Newly listed Nasdaq biotech with an IPO of $317.5M.
